

FINALISTS 2022

Executive of the Year – Private companies and those with a market cap <\$7bn
Scrip's Executive of the Year Award is designed to acknowledge excellence in the leadership of private and pharmaceutical and biotechnology companies with a market cap of less than \$7bn.

SCRIP AWARDS 2022

30 NOVEMBER 2022 · ROYAL LANCASTER, LONDON

Renée Aguiar-Lucander

Chief Executive Officer of Calliditas Therapeutics

From its initial listing on the Swedish stock exchange in 2018 – in what was one of the largest European IPOs that year – via a successful listing on the US NASDAQ in June 2020 raising \$90m, Aguiar-Lucander has now led Calliditas to approvals on both sides of the Atlantic for its lead asset, Tarpeyo (Nefecon), for IgA nephropathy, an orphan chronic autoimmune kidney disease for which there were no treatments available.

Stéphane Boissel

Chief Executive Officer and Chairman of SparingVision

Since his appointment as CEO in 2020, Boissel has expanded SparingVision's pipeline from one to six assets, and in October 2021, signed a deal with Intellia Therapeutics, one of the world's leading gene editing companies, to take forward their CRISPR-Cas9 technologies for ocular diseases. Boissel has also led SparingVision through the acquisition of Gamut Therapeutics, a rare step for a young biotech company.

Scott Braunstein

Chief Executive Officer of Marinus Pharmaceuticals

Under Braunstein's leadership, Marinus received its first FDA approval in March 2022 for Ztalmy (ganaxolone), the first treatment for seizures associated with CDKL5 deficiency disorder, a rare form of genetic epilepsy that predominately affects children. Braunstein has also expanded Marinus' employee base and shaped its culture significantly, being a champion for the company's diversity, equity and inclusion efforts. Braunstein was appointed CEO in August 2019 and has served on the board since 2018.

Bahija Jallal

Chief Executive Officer of Immunocore

Taking up the position of CEO in 2019, Jallal has led Immunocore during a transformational period, from an early-stage UK biotech to the world's first company to commercialize T-cell receptor (TCR) therapeutics. Under her leadership, with the US approval of the first approved therapy for uveal melanoma, Kimmtrak (tebentafusp), Immunocore has established itself as the leader in the development of TCR therapies and its pipeline includes five clinical stage programs in oncology and infectious disease.

John Leonard

President and Chief Executive Officer of Intellia Therapeutics

Since its 2014 launch, AbbVie veteran Leonard has led Intellia through all of its major milestones, including its 2016 initial public offering and, most notably, its June 2021 landmark data announcement showing that it is possible to treat, and potentially cure, a broad range of diseases through genome editing. This breakthrough made Intellia the first team in history – commercial or academic – to fully harness CRISPR's potential as a medicine. Today, the company has four programs in clinical trials.

Michael M Morrissey

President and Chief Executive Officer of Exelixis

As president and CEO, Morrissey has led Exelixis through a significant period of growth for its discovery, development and commercial functions. In addition to overseeing the expansion of the company's successful Cometriq/Cabometyx (cabozantinib) franchise to exceeded \$1bn in US net revenues in 2021, Morrissey has helped to usher in a new era of R&D, including building a differentiated clinical pipeline spanning small molecules and biologics, antibody-drug conjugates and other biotherapeutics addressing highly promising targets.

Winners are announced at the Awards ceremony and dinner on Wednesday 30th November at the Royal Lancaster Hotel, London.